A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal

Study acronym: BRITE
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Feb 29, 2028 to Feb 25, 2028
    • Start date changed from estimate of Aug 31, 2026 to Aug 25, 2026
    v2
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
Trial Details
NCT Number NCT07784387
Lead Sponsor Janssen-Cilag Farmaceutica Ltda.
Conditions
(from sponsor)		 Urinary Bladder Neoplasms
Related terms Urinary Bladder Neoplasms
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov